|
1
|
Sheikhlary S, Lopez DH, Moghimi S, Sun B. Recent Findings on Therapeutic Cancer Vaccines: An Updated Review. Biomolecules 2024; 14:503. [PMID: 38672519 PMCID: PMC11048403 DOI: 10.3390/biom14040503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2024] [Revised: 04/06/2024] [Accepted: 04/16/2024] [Indexed: 04/28/2024] Open
Abstract
Cancer remains one of the global leading causes of death and various vaccines have been developed over the years against it, including cell-based, nucleic acid-based, and viral-based cancer vaccines. Although many vaccines have been effective in in vivo and clinical studies and some have been FDA-approved, there are major limitations to overcome: (1) developing one universal vaccine for a specific cancer is difficult, as tumors with different antigens are different for different individuals, (2) the tumor antigens may be similar to the body's own antigens, and (3) there is the possibility of cancer recurrence. Therefore, developing personalized cancer vaccines with the ability to distinguish between the tumor and the body's antigens is indispensable. This paper provides a comprehensive review of different types of cancer vaccines and highlights important factors necessary for developing efficient cancer vaccines. Moreover, the application of other technologies in cancer therapy is discussed. Finally, several insights and conclusions are presented, such as the possibility of using cold plasma and cancer stem cells in developing future cancer vaccines, to tackle the major limitations in the cancer vaccine developmental process.
Collapse
Affiliation(s)
- Sara Sheikhlary
- Department of Biomedical Engineering, College of Engineering, The University of Arizona, Tucson, AZ 85721, USA
| | - David Humberto Lopez
- Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ 85721, USA; (D.H.L.); (S.M.)
| | - Sophia Moghimi
- Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ 85721, USA; (D.H.L.); (S.M.)
| | - Bo Sun
- Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ 85721, USA; (D.H.L.); (S.M.)
| |
Collapse
|
|
2
|
Hosea R, Hillary S, Naqvi S, Wu S, Kasim V. The two sides of chromosomal instability: drivers and brakes in cancer. Signal Transduct Target Ther 2024; 9:75. [PMID: 38553459 PMCID: PMC10980778 DOI: 10.1038/s41392-024-01767-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Revised: 01/18/2024] [Accepted: 02/06/2024] [Indexed: 04/02/2024] Open
Abstract
Chromosomal instability (CIN) is a hallmark of cancer and is associated with tumor cell malignancy. CIN triggers a chain reaction in cells leading to chromosomal abnormalities, including deviations from the normal chromosome number or structural changes in chromosomes. CIN arises from errors in DNA replication and chromosome segregation during cell division, leading to the formation of cells with abnormal number and/or structure of chromosomes. Errors in DNA replication result from abnormal replication licensing as well as replication stress, such as double-strand breaks and stalled replication forks; meanwhile, errors in chromosome segregation stem from defects in chromosome segregation machinery, including centrosome amplification, erroneous microtubule-kinetochore attachments, spindle assembly checkpoint, or defective sister chromatids cohesion. In normal cells, CIN is deleterious and is associated with DNA damage, proteotoxic stress, metabolic alteration, cell cycle arrest, and senescence. Paradoxically, despite these negative consequences, CIN is one of the hallmarks of cancer found in over 90% of solid tumors and in blood cancers. Furthermore, CIN could endow tumors with enhanced adaptation capabilities due to increased intratumor heterogeneity, thereby facilitating adaptive resistance to therapies; however, excessive CIN could induce tumor cells death, leading to the "just-right" model for CIN in tumors. Elucidating the complex nature of CIN is crucial for understanding the dynamics of tumorigenesis and for developing effective anti-tumor treatments. This review provides an overview of causes and consequences of CIN, as well as the paradox of CIN, a phenomenon that continues to perplex researchers. Finally, this review explores the potential of CIN-based anti-tumor therapy.
Collapse
Affiliation(s)
- Rendy Hosea
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, 400045, China
- The 111 Project Laboratory of Biomechanics and Tissue Repair, College of Bioengineering, Chongqing University, Chongqing, 400044, China
| | - Sharon Hillary
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, 400045, China
- The 111 Project Laboratory of Biomechanics and Tissue Repair, College of Bioengineering, Chongqing University, Chongqing, 400044, China
| | - Sumera Naqvi
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, 400045, China
- The 111 Project Laboratory of Biomechanics and Tissue Repair, College of Bioengineering, Chongqing University, Chongqing, 400044, China
| | - Shourong Wu
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, 400045, China.
- The 111 Project Laboratory of Biomechanics and Tissue Repair, College of Bioengineering, Chongqing University, Chongqing, 400044, China.
- Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing University, Chongqing, 400030, China.
| | - Vivi Kasim
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, 400045, China.
- The 111 Project Laboratory of Biomechanics and Tissue Repair, College of Bioengineering, Chongqing University, Chongqing, 400044, China.
- Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing University, Chongqing, 400030, China.
| |
Collapse
|
|
3
|
Barbier MA, Ferland K, De Koninck H, Doucet EJ, Dubourget L, Kim M, Cattier B, Morissette A, Bchetnia M, Larouche D, Kim DH, St-Jean G, Germain L. Cancer Spheroids Embedded in Tissue-Engineered Skin Substitutes: A New Method to Study Tumorigenicity In Vivo. Int J Mol Sci 2024; 25:1513. [PMID: 38338792 PMCID: PMC10855415 DOI: 10.3390/ijms25031513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2023] [Revised: 01/20/2024] [Accepted: 01/23/2024] [Indexed: 02/12/2024] Open
Abstract
Tumorigenic assays are used during a clinical translation to detect the transformation potential of cell-based therapies. One of these in vivo assays is based on the separate injection of each cell type to be used in the clinical trial. However, the injection method requires many animals and several months to obtain useful results. In previous studies, we showed the potential of tissue-engineered skin substitutes (TESs) as a model for normal skin in which cancer cells can be included in vitro. Herein, we showed a new method to study tumorigenicity, using cancer spheroids that were embedded in TESs (cTES) and grafted onto athymic mice, and compared it with the commonly used cell injection assay. Tumors developed in both models, cancer cell injection and cTES grafting, but metastases were not detected at the time of sacrifice. Interestingly, the rate of tumor development was faster in cTESs than with the injection method. In conclusion, grafting TESs is a sensitive method to detect tumor cell growth with and could be developed as an alternative test for tumorigenicity.
Collapse
Affiliation(s)
- Martin A. Barbier
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Department of Surgery, Faculty of Medicine, Université Laval, Quebec, QC G1V 0A6, Canada
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - Karel Ferland
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Department of Surgery, Faculty of Medicine, Université Laval, Quebec, QC G1V 0A6, Canada
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - Henri De Koninck
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Department of Surgery, Faculty of Medicine, Université Laval, Quebec, QC G1V 0A6, Canada
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - Emilie J. Doucet
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Department of Surgery, Faculty of Medicine, Université Laval, Quebec, QC G1V 0A6, Canada
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - Ludivine Dubourget
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Department of Surgery, Faculty of Medicine, Université Laval, Quebec, QC G1V 0A6, Canada
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - MinJoon Kim
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Department of Surgery, Faculty of Medicine, Université Laval, Quebec, QC G1V 0A6, Canada
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - Bettina Cattier
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Department of Surgery, Faculty of Medicine, Université Laval, Quebec, QC G1V 0A6, Canada
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - Amélie Morissette
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - Mbarka Bchetnia
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - Danielle Larouche
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| | - Dong Hyun Kim
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
- Department of Dermatology, CHA Bundang Medical Center, CHA University, 59 Yatap-ro, Bundang-gu, Seongnam-si 463-712, Gyeonggi-do, Republic of Korea
| | - Guillaume St-Jean
- Department of Pathology and Microbiology, Faculty of Veterinary Medicine, Université de Montréal, Saint-Hyacinthe, QC J2S 2M2, Canada;
| | - Lucie Germain
- The Tissue Engineering Laboratory (LOEX), Université Laval’s Research Center, Quebec, QC G1V 0A6, Canada; (M.A.B.); (K.F.); (H.D.K.); (E.J.D.); (L.D.); (M.K.); (B.C.); (A.M.); (M.B.); (D.L.); (D.H.K.)
- Department of Surgery, Faculty of Medicine, Université Laval, Quebec, QC G1V 0A6, Canada
- Regenerative Medicine Division, CHU de Québec-Université Laval Research Centre, Quebec, QC G1J 1Z4, Canada
| |
Collapse
|
|
4
|
Lezmi E, Jung J, Benvenisty N. High prevalence of acquired cancer-related mutations in 146 human pluripotent stem cell lines and their differentiated derivatives. Nat Biotechnol 2024:10.1038/s41587-023-02090-2. [PMID: 38195986 DOI: 10.1038/s41587-023-02090-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2023] [Accepted: 12/05/2023] [Indexed: 01/11/2024]
Abstract
To survey cancer-related mutations in human pluripotent stem cells and their derivatives, we analyzed >2,200 transcriptomes from 146 independent lines in the NCBI's Sequence Read Archive. Twenty-two per cent of samples had at least one cancer-related mutation; of these, 64% had TP53 mutations, which conferred a pronounced selective advantage, perturbed target gene expression and altered cellular differentiation. These findings underscore the need for robust surveillance of cancer-related mutations in pluripotent cells, especially in clinical applications.
Collapse
Affiliation(s)
- Elyad Lezmi
- Department of Genetics, The Azrieli Center for Stem Cells and Genetic Research, Silberman Institute of Life Sciences, The Hebrew University, Jerusalem, Israel
| | - Jonathan Jung
- Department of Genetics, The Azrieli Center for Stem Cells and Genetic Research, Silberman Institute of Life Sciences, The Hebrew University, Jerusalem, Israel
| | - Nissim Benvenisty
- Department of Genetics, The Azrieli Center for Stem Cells and Genetic Research, Silberman Institute of Life Sciences, The Hebrew University, Jerusalem, Israel.
| |
Collapse
|